financetom
Business
financetom
/
Business
/
Insmed Says Full-year Revenue Expected to Rise 19%
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Insmed Says Full-year Revenue Expected to Rise 19%
Jan 10, 2025 10:05 AM

12:47 PM EST, 01/10/2025 (MT Newswires) -- Insmed ( INSM ) said Friday said it expects to report full-year 2024 global net product sales of its drug Arikayce of $363.7 million, up 19% year over year.

The results are preliminary and subject to adjustment, the company said. Insmed ( INSM ) expects to report its actual results in late February.

Analysts polled by FactSet expect $356.8 million in full-year revenue.

Price: 65.21, Change: -0.51, Percent Change: -0.78

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2025 - www.financetom.com All Rights Reserved